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Abstract
Background: This study aimed to assess the efficacy and safety of repeat hepatectomy for recurrent hepatocellular 
carcinoma (HCC).
Methods: Thirty-seven patients who underwent a curative repeat hepatectomy in our hospital were retrospectively 
studied. An extensive database literature search was performed to obtain for all relevant studies.
Results: In our series, there were no perioperative deaths during repeat hepatectomy for recurrent HCC. Patients 
survival after repeat hepatectomy were similar to 429 patients undergoing initial hepatectomy. A computerized search 
of the Medline and PubMed databases found 29 retrospective studies providing relevant data in 1149 patients were 
included for appraisal and data extraction. After the repeat hepatectomy, postoperative morbidity ranged from 6.2% to 
68.2% with a median per cohort of 23.5 per cent. There were 7 perioperative deaths (0.7 per cent of 993 for whom 
mortality data were provided). The overall median survival ranged from 21 to 61.5 months, with 1 -, 3 -, and 5-year 
survival of 69.0% to 100%, 21.0% to 87.0%, and 25.0% to 87.0%, respectively.
Conclusions: Repeat hepatectomy can be performed safely and is associated with long-term survival in a subset of 
patients with recurrent HCC. However, the findings have to be carefully interpreted due to the lower level of evidence. 
A randomized controlled study is needed to compare repeat hepatectomy and other modalities for recurrent HCC.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in the world, responsible for 500,000 deaths
globally every year, and its incidence is increasing world-
wide because of the dissemination of hepatitis B and C
virus infection [1]. With advances in surgical techniques
and perioperative care, results of hepatic resection for
HCC have greatly improved. Nonetheless, the long-term
survival after hepatectomy remains unsatisfactory
because of the high incidence of recurrence. Intrahepatic
recurrence are the most common and are seen in up to
68-96% of patients [2]. Thus, effective therapeutic strate-
gies of intrahepatic recurrence is critical in prolonging
survival after resection of HCC.
Transcatheter arterial chemoembolization (TACE) is
most commonly used as a treatment modality for intra-
hepatic recurrence. However, the role of TACE therapy in
the treatment of postoperative recurrence is pessimistic,
with 5-year survival rates only range from 0% to 27%,
even with repeated TACE treatment [3-5]. Hepatic resec-
tion is the only therapy that is potentially curative for
liver tumors, and offers patients a chance of long-term
survival. Currently, many treatment centers advocate the
repeat hepatectomy is the first choice of treatment for
recurrent HCC and have claimed that it is safe and that it
has similar survival results to initial hepatectomy [6].
However, due to the limited numbers of patients who
undergo resection at a single institute, a thorough assess-
ment of the outcome of repeat hepatectomy for recurrent
HCC has not been reported.
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In this study, based on literature review and retrospec-
tive results from our institution, we assessed the efficacy




From December 1999 and June 2005, 462 patients with
HCC underwent initial hepatic resection with curative
intent at the Department of Special Treatment and Liver
transplantation in Eastern Hepatobiliary Surgery Hospi-
tal, Second Military Medical University, Shanghai, China.
Curative resection was defined as grossly complete
removal of the tumor with a clear microscopic margin.
Four patients died within 1 month after operation and 29
patients lost follow-up were excluded from the present
study. The remaining 429 patients were followed-up
every 1 month by tumor marker (alpha-fetoprotein, AFP)
analysis and ultrasound or computed tomography at least
every 3 months in the first year after hepatectomy, and
then at gradually increasing intervals. Recurrence was
identified by new lesions on imaging with appearances
typical of HCC or a rising AFP level. When findings on
ultrasound or computed tomography were inconclusive,
hepatic angiography with infusion of iodized oil was per-
formed.
During a median follow-up period of 25 months, 276
(64.3%) patients developed intrahepatic recurrence, and
37 patients underwent a second hepatectomy (rate of
repeat hepatectomy, 13.4%). There were 32 men and 5
women with a median age of 52 years (range, 16 to 81
years) at the time of the second operation. Our selection
criteria for repeat resection were the same as those for
initial resection: good general condition, favorable Child-
Pugh Class (A plus selected Grade B), adequate liver rem-
nant, and the ability to technically resect all tumor with
curative intent. Treatments for unresectable intrahepatic
recurrence were TACE (n = 126), local thermal and
chemical ablation (n = 45), and only conservative man-
agement (n = 68).
B) Operative procedures
Surgery was performed through a right or left subcostal
incision or bilateral subcostal incision. After an explor-
atory laparotomy, the liver was fully mobilized from all its
peritoneal attachments. The liver was then assessed with
intraoperative ultrasound to assess the extent of local dis-
ease, and to detect any extrahepatic metastases or perito-
neal seedings. A Pringle maneuver was carried out for
controlling the portal triad, with a clamp/unclamp time
of 15 min/5 min, during hepatic parenchymal transection
if necessary. Transection of the liver was achieved using
the Kelly clamp crushing technique. The vascular and bil-
iary radicals were ligated and divided intrahepatically.
Fibrin glue was applied to the raw surface of the liver.
Nomenclature for the extent of hepatic resection fol-
lows the Brisbane 2000 Guidelines for Liver Anatomy and
Resection [7]. Major resection were defined as a resection
of 3 or more segments, whereas minor resection were
defined as a resection of 2 or fewer segments according to
the Couinaud classification. Perioperative mortality was
defined as any death either within 30 days of surgery or
occurring in the hospital.
C) Statistical analysis
Categorical variables were compared by using the Chi-
square test or the Fisher exact test as appropriate. Contin-
uous data were expressed as the mean ± standard devia-
tion and compared by one-way ANOVA. Mann-Whitney
U test was used to evaluate differences between groups.
Overall survival rates were estimated with the Kaplan-
Meier method and compared by log-rank test. The Cox
proportional hazards model was used for multivariate
analysis of prognostic factors. All statistical analyses were
performed using SPSS for Windows (version 11.0; SPSS




Electronic literature searches were performed to identify
all published peer-review medical articles on repeat
hepatectomy for recurrent HCC. Medline and PubMed
databases were searched from the time of inception to
November 2009. The following Mesh search headings
were used: "recurrent hepatocellular carcinoma," "repeat
hepatectomy," "repeat hepatic resection," and "second
hepatectomy." Reference lists of all retrieved articles were
manual searched for additional studies.
B) Selection criteria
For inclusion in review, studies that reported at least 10
patients and that used repeat hepatectomy for recurrent
HCC with a curative intent were retrieved. Studies were
classified into 4 levels of evidence as follows: level 1, ran-
domized controlled trials; level 2, controlled clinical tri-
als; level 3, observational studies with matched control
groups; and level 4, observational observational case
series. Letters, reviews, abstracts, editorials, expert opin-
ions, non-English language papers and animal studies
were excluded. Studies that included other liver cancer
diagnoses were excluded. In the case of multiple publica-
tion of a given cohort of patients, the first published arti-
cle was included in our analysis. However, if a more
recent publication corroborated the results of a larger
cohort, longer follow-up, or both, we included this more
recent publication.
C) Data extraction and critical appraisal
Data extraction was performed independently by two
authors (Y.M.Z. and B.L., respectively) using predefined
criteria. The two investigators independently reviewed allZhou et al. World Journal of Surgical Oncology 2010, 8:55
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the retrieved studies that met the inclusion and exclusion
criteria. Discrepancies between the two reviewers were
resolved by discussion and consensus. Each included
study was appraised for its level of evidence. The two
reviewers extracted data on the following categories: (1)
number of patients undergoing surgery for recurrent
HCC; (2) resectability rate; (3) postoperative morbidity
and mortality; (4) overall survival; (5) prognostic factors.
A meta-analysis was not possible because none of the
studies were randomized trials. All relevant text, tables
and figures were reviewed for data extraction. Data are
presented as median (range) unless otherwise stated.
Results
The author's experience
Table 1 shows a comparison of the clinicopathological
features, operative procedures and perioperative out-
comes among the 462 patients who underwent initial
hepatectomy and the 37 patients who underwent repeat
resection. The initial resection group had larger tumor
size and higher aminotransferase level. There were no
differences between initial and repeat hepatectomy with
respect to Child-Pugh classifications, serum AFP level,
total bilirubin level, tumors number and location, tumor
capsule formation, vascular invasion, Edmondson-Steiner
grade.
Major resections were performed more frequently in
initial hepatectomy. Combined organ resection was com-
mon in initial resection (24.6%). Similarly, initial resec-
tion group had more intraoperative blood loss. However,
there were no differences between two groups in terms of
operating time, clumping time, transfusion requirement,
perioperative morbidity and mortality.
The overall 1-year, 3-year, and 5-year survival rates
after initial hepatectomy in the whole group of 429
patients were 91.2%, 69.4%, and 42.5%, respectively, these
were similar to 37 patients after repeat hepatectomy
(94.6%, 70.3% and 43.7%, respectively).
Figure 1 shows the comparison of survival rates after
HCC recurrence according to the types of treatment. The
survival rate of patients who had repeat hepatectomy was
significantly better than the rates of patients who had
non-surgical treatment. The 1-year, 3-year, and 5-year
survival rates of patients with TACE were 74.3%, 33.3%,
and 11.1%, respectively. Patients who underwent local
ablation had 1-year, 3-year, and 5-year survival rates of
46.6%, 20.3%, and 8.8%, respectively. For patients treated
with conservative management after recurrence had sur-
vival rates of 24.2%, 0%, and 0%, respectively.
Univariate analysis revealed that vascular invasion,
multiple recurrent tumors, and a recurrence-free interval
of ≤1 year were adverse prognostic factors for survival
after repeat hepatectomy (Table 2).
Multivariate analysis indicated that the recurrence-free
interval of ≤1 year (risk ratio = 2.665, 95% confidence
interval = 0.964-7.364, P = 0.05) was the only indepen-
dent prognostic factor for overall survival after repeat
hepatectomy.
Literature search
A) Quantity and quality of evidence
This electronic search resulted in the identification of 256
publications. On initial evaluation of these abstracts, 36
studies remained. Manual review of the citation lists
identified a further 4 studies. A total of 40 potentially rel-
evant publications were retrieved for further evaluation.
Of these, 6 were ex cluded for the following reasons: 1
study evaluating the impact of obesity on the surgical
outcome following repeat hepatic resection patients with
recurrent HCC, 2 studies lacks information of survival, 3
were earlier publications from the same treatment center.
Another 5 were excluded because the number of patients
in each study was fewer than 10. Finally, 29 studies
matched the selection criteria and were therefore
included. All studies were retrospective in design and
their size ranged from 11 to 149 patients. Of these, 28
studies were observational cases series with no control
groups and were classified as level-4 evidence [5,8-34], 1
study compared percutaneous radiofrequency ablation
versus repeat hepatectomy was classified as level-3 evi-
dence [35].
B) Selection criteria for repeat hepatectomy
So far, no consensus has been reached concerning the
standard selection criteria for repeat hepatic resection.
Generally, patients who had a good performance status
and a liver functional reserve, if oncologically radical
operation was possible, the patients were selected for
hepatectomy [11-33,35].
C) Characteristics of the study population
Characteristics of the 29 eligible studies are listed in Table
3. These papers described 1149 patients underwent
repeat hepatectomy for recurrent HCC. The rate of
repeat hepatectomy ranged from 8.7% to 44.0% (median
= 22.8%). The mean age in 17 studies providing data on
age ranged from 45.0-66.9 years (median = 59.5). Male:
female ratio in the pooled data was 4.2: 1. Median/mean
(range) recurrent intervals between the initial and repeat
hepatectomy ranged from 6 to 31 (median = 22.4)
months. 37.5%-83.3% of patients had solitary intrahepatic
recurrence (median = 64.2%).
D) Operative strategy
At the time of repeat recection, the proportion of patients
who underwent minor resection ranged from 71.4% to
100% (median = 95.5%). The median/mean operating
time ranged from 136 to 365 (median = 267) min. The
median/mean estimated blood loss ranged from 211 to
1980 (median = 603) ml (Table 4).Zhou et al. World Journal of Surgical Oncology 2010, 8:55
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Page 4 of 10
E) Morbidity and Mortality
After the repeat hepatectomy, data were available on
postoperative complication rate for recurrent HCC in 12
studies covering 596 patients, with a median (range) mor-
bidity of 23.5% (6.2-68.2%). A total of 7 deaths were
reported in 24 studies covering 993 patients, giving a
mean mortality rate of 0.7 per cent. The reported mortal-
ity rate in these studies ranged from 0 to 8.0 per cent
(Table 4).
F) Survival
The overall median survival since the repeat hepatectomy
ranged from 21 to 61.5 months, with 1-, 3-, and 5-year
Table 1: Comparison of clinicopathological features, operative procedures and perioperative outcomes between the 






Median age at operation 
(years)
49.0 52.0 NS
Gender (male/female) 419/43 32/5 NS
HBV-positive 451 (97.6) 37 (100) NS
Child-Pugh class A 424 (91.8) 37 (100) NS
Serum AFP > 100 ng/mL 212 (45.8) 13 (35.1) NS
Total bilirubin (umol/L) 14.5 ± 8.9 16.4 ± 8.3 NS
Serum albumin (g/L) 41.8 ± 3.6 41.2 ± 3.7 NS
Serum ALT (IU/L) 56.3 ± 51.8 36.7 ± 11.4 0.028
Serum AST (IU/L) 53.4 ± 52.7 33.0 ± 10.1 0.007
Tumor size in diameter (cm) 7.3 ± 4.8 3.3 ± 1.9 <0.001
Tumor location NS
Right lobe 326 (70.5) 23 (62.1)
Left lobe 134 (29.0) 14 (37.8)
Both lobe 12 (2.5) 0
Cirrhotic liver 238 (51.6) 20 (54) NS
Solitary tumor 374 (80.9) 28 (75.6) NS
Tumor capsule formation 291 (62.9) 26 (70.2) NS
Vascular invasion 272 (58.2) 19 (51.3) NS
Edmonson-Steiner grade NS
G1-G2 31 (6.7) 4 (10.8)
G3-G4 431 (93.3) 33 (89.2)
Extent of hepatectomy 0.018
Major resection 133 (28.7) 4 (10.8)
Minor resection 329 (56.8) 33 (89.2)
Combined organ resection 114 (24.6) 0 0.001
Operation time (min) 228.6 ± 68.4 211.8 ± 67.0 NS
Clamping time (min) 18.5 ± 8.2 16.7 ± 10.4 NS
Blood loss (mL) 690.0 ± 762.8 364.2 ± 293.4 0.002
Need for blood transfusion 64 (13.8) 6 (16.2) NS
Postoperative complication 147 (31.8) 9 (24.3) NS
Mortality 4 (0.8) 0 NS
Postoperative hospital stay 
(days)
10.6 ± 3.2 11.5 ± 3.1 NS
Hx: hepatectomy. HBV: hepatitis B virus. AFP: alpha-fetoprotein.
ALT: alanine aminotransferase. AST: aspartate aminotransferase.Zhou et al. World Journal of Surgical Oncology 2010, 8:55
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survival of 69.0% to 100%, 21.0% to 87.0%, and 25.0% to
87.0%, respectively (Table 4).
G) Significant prognostic factors for survival
A few studies have identified the independent poor prog-
nostic factors after a repeat hepatic resection. Factors
related to initial hepatectomy included the following:
portal vein invasion [19,34], multiple lesion [26], and
short recurrence-free interval between initial and repeat
hepatectomy (<1 year [26,35], or <1.5 year [34]). Factors
related to repeat hepatectomy included the following:
female gender, younger age, tumor grade [18], micro-
scopic vascular invasion [31], recurrent tumors >3 cm,
and serum albumin level <35 g/L [35].
Discussion
The postoperative recurrence of HCC remains the major
cause of death and the main obstacle to long-term sur-
vival. The remnant liver is the primary site of tumor
recurrence, the recurrence rate is 36.8-78% in current
systemic review. Although various therapeutic modalities
have been used for the treatment of recurrent HCC,
hepatic resection is the only therapy that is potentially
Figure 1 Overall survival from the time recurrence of patients treated with repeat resection (Gp 1), TACE (Gp 2), local ablation (Gp 3), and 
conservative management (Gp 4).Zhou et al. World Journal of Surgical Oncology 2010, 8:55
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Serum AFP (ng/mL) NS
>100 13 50
≤100 24 59
Serum total bilirubin (umol/L) NS
>20 8 35
≤20 29 63
Serum ALT (IU/L) NS
>40 12 37
≤40 25 59
Serum AST (IU/L) NS
>40 7 48
≤40 30 59
Background liver tissue NS
Non-cirrhotic 17 64
Cirrhotic 20 44
Tumors capsule formation NS
Absent 11 48
Present 26 64
Tumors size (cm) NS
>3 15 50
≤3 22 59









Recurrence-free interval (year) <0.001
>1 29 64
≤1 8 29







































































































Table 3: Characteristics of the included studies


















size (<3 cm) (%)
Lange [8] 1989 -- 9 -- 11 9/2 45 36 54.5 27
Nakajima [9] 1993 36.8 -- 28.5 14 -- -- 50 64.2 64.2
Matsuda [10] 1993 40 18 44 16 13/3 63.3 100 -- --
Wu [11] 1993 -- -- -- 72 66/6 45.8 63.9 -- --
Zhou [12] 1993 48.2 -- 35 65 -- -- -- -- --
Kakazu [13] 1993 78 26* 11 24 19/5 59.5 -- 62.5 --
Suenaga [14] 1994 61.2 33.3* 24.3 18 13/5 56.9 88.8 72.2 67
Lee [15] 1995 40.8 18 31.2 25 17/8 55.8 76 60 32
Nagasue [16] 1996 -- 21* 30 50 36/14 59 76 70 --
Shuto [17] 1996 57 16 31 27/4 60 94 64.5 --
Hu [18] 1996 -- 23 -- 59 46/13 52 -- 66.1 --
Shimada [19] 1998 -- -- -- 41 33/8 -- 56 65.8 70.7
Arii [20] 1998 -- -- 12.6 22 16/6 60 68.2 63.6 --
Farges [21] 1998 67 -- 16.8 15 -- -- -- -- --
Poon [5] 1999 43 6 10 11 -- -- -- -- --
Nakajima [22] 2001 60.6 31 21 12 10/2 62.3 41.6 83.3 --
Sugimachi [23] 2001 63.3 -- 26 78 -- -- -- -- --
Tanabe [24] 2001 56.9 -- 19.6 21 -- -- -- 76.1 --
Shen [25] 2002 34.6 -- 22.4 20 -- -- -- -- --
Minagawa [26] 2003 54.7 -- 31 67 56/11 62.7 68.6 55.2 76.1
Chen [27] 2004 56.5 9.0 11.8 34 -- -- -- -- --
Sun [28] 2005 -- 26.8 -- 57 52/5 52.3 85.9 82.4 --
Kobayashi [29] 2006 55.2 -- 29 60 -- -- -- -- --
Tralhão [30] 2007 40 27 21 16 14/2 61.3 93.7 43.7 --
Itamoto [31] 2007 58 22.4 25 84 64/20 66 67 63 63
Wu [32] 2009 54.4 26.3 23.2 149 114/35 59ï¿½0 -- 79.1 --
Kawano [33] 2009 67.4 12 8.8 13 -- -- -- -- --
Nagano [34] 2009 45.5 22.8 24 20/4 66.9 -- 37.5 --
Liang [35] 2008 -- -- 44 39/5 48.8 -- 77.2 59.0
* meanZhou et al. World Journal of Surgical Oncology 2010, 8:55
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curative for liver tumors, and offers patients a chance of
long-term survival. However, repeat hepatectomy is con-
sidered unsuitable for majority of patients with intrahe-
patic recurrence. The rate of repeat hepatectomy for
HCC recurrence ranged from 7% to 30% in the present
systematic review (the figure in our current study was
13.4%). The main reason is the low rate of resectability in
patients with intrahepatic recurrence because of the mul-
tifocality, location of the tumor, or degree of cirrhosis
[33].
R e p e a t  h e p a t e c t o m y  i s  m o r e  t e c h n i c a l l y  c h a l l e n g i n g
than initial resection because of impaired liver function
due to the progression of hepatitis, the presence of adhe-
sion, and modifications in the anatomy by the previous
operation. However, our study and previous reports com-
pared the perioperative outcomes after initial and repeat
hepatectomy and did not find any statistically significant.
The overall perioperative morbidity rate ranged from
6.2% to 68.2% (24.3% in our series). These complications
were easily managed with conservative management.
Although data on postoperative death were provided in
only 993 of 1149 patients, a mortality rate of 0.7 per cent
is very low. Furthermore, repeat hepatectomy can achieve
a long-term survival for patients with recurrent HCC.
The overall median survival since the repeat hepatectomy
ranged from 23 to 56 months, with 5-year survival of 25%
to 87%, and the figure was 43.7% in our series. Moreover,
several studies showed that there was no marked differ-
ence in survival after the initial and repeat hepatectomy
[5,11,14,18,19,26,29,32,34]. These data suggest that
repeat hepatectomy is a safely and effective therapy for
intrahepatic recurrence.
Predictably, nonsurgical treatment continues to be a
factor associated with poor survival of patients with
recurrent HCC [5,24,27]. The survival outcome of repeat
hepatectomy is considerably better than that of nonsurgi-
cal or conservative treatment [5,9,10,12,14-17,21,23-
25,27,30,32]. It should be noted that the favourable
results of repeat hepatectomy might partly be due to a
high selection of patients with a well preserved liver func-
tion and limited intrahepatic tumor spread. Patients who
did not undergo repeat hepatectomy may have had
poorer liver functional reserve and/or too advanced
recurrent tumor [32]. The clinicopathological back-
grounds of the patients in the different treatment groups
Table 4: Summary of outcomes reported in the included studies
Variable No. of studies with available information Median (range)
Intrahepatic recurrences rate after Initial 
Hx (%)
215, 9, 10, 12-15, 17, 21-27, 29-34 55.2 (34.6-78)
Median/mean recurrent intervals (months) 
after initial Hx
155, 8, 10, 13-16, 18, 22, 27, 28, 30-33 22.4 (6-33.3)
Resectability rate (%) 235, 9, 10, 12-17, 20-27, 29-34 22.8 (8.7-44)
No. of repeat Hx 295, 9-35 1149*
Mean age (years) 178, 10, 11, 13-17, 20, 22, 26, 28, 30-32, 34, 35 59.5 (45-66.9)
Male (%) 198, 10, 11, 13-19, 22, 26, 28, 30-32, 34, 35 81.2 (68-91.6)
Liver cirrhosis (%) 158-11, 14-17, 19, 20, 22, 26, 28, 30, 31 68.6 (36-100)
Solitary recurrent HCC (%) 198, 9, 13-20, 22, 24, 26, 28, 30-32,34, 35 64.2 (37.5-83.3)
Maxium tumor size <3 cm (%) 88, 9, 14, 15, 19, 26, 31, 35 63.6 (27-76.1)
Minor resection (%) 188-18, 22, 26, 30- 32, 34 95.5 (71.4-100)
Median/mean operating time (min) 913, 15, 16, 19, 22, 26, 30, 32, 34 267(136-365)
Median/mean blood loss (mL) 1313-16, 19, 22, 26, 28-30, 32, 34, 35 603 (211-1980)
Morbidity (%) 1210, 13, 15, 16, 18, 22, 28-32, 35 23.5 (6.2-68.2)
Mortality (%) 245, 8-10, 12-23, 26, 28-32, 34, 35 0 (0-8.0)
Overall survival after recurrence
Median time (months) 88, 10, 14, 15, 18, 22, 28, 33 27.1 (21-61.5)
1-year (%) 255, 8-22, 25-31,34, 35 91.0(69-100)
3-year (%) 265, 8-24, 26-31, 34, 35 63.4 (21.0-87.0)
5-year (%) 225, 9, 11-14, 16, 17, 19, 21, 23, 24, 26-35 48.5(25.0-87.0)
Hx: hepatectomy. HCC: hepatocellular carcinoma. * totalZhou et al. World Journal of Surgical Oncology 2010, 8:55
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were quite different, so comparisons among the various
treatments would be of limited value.
Postoperative HCC recurrence is thought to take place
in two ways, intrahepatic metastasis (IM) through the
portal vein in the residual liver and metachronous, multi-
centric hepatocarcinogenesis based on chronic hepatitis
[36]. Generally, the two kinds of recurrence can roughly
be distinguished according to the interval after hepatec-
tomy. The early recurrences (≤1 year) may arise mainly
from IM, whereas most of the late recurrences (>1 year)
are probably multicentric in origin [36]. Early recurrence
have been found to be a significant prognostic factor after
repeat hepatectomy in two reports [26,35], and our study
confirmed the same findings. These data suggested that
patients with late recurrences may be more favorable can-
didates for repeat hepatectomy.
Conclusions
Repeat hepatectomy can be performed safely and is asso-
ciated with long-term survival in a subset of patients with
recurrent HCC. Although promising, it must also be
emphasized that all current available studies are low level
evidence. Thus, randomized controlled study is needed
to compare repeat hepatectomy and other modalities for
recurrent HCC.
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